Swedish Orphan Biovitrum AB (publ) (FRA:B6E)

Market Cap	11.03B +13.8%
Revenue (ttm)	2.52B +9.5%
Net Income	1.18M -99.6%
EPS	0.00 -99.6%
Shares Out	n/a
PE Ratio	9,376.21
Forward PE	19.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	115
Open	31.84
Previous Close	31.34
Day's Range	31.84 - 31.84
52-Week Range	22.40 - 33.24
Beta	n/a
RSI	54.85
Earnings Date	Feb 5, 2026

About FRA:B6E

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,890
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: B6E

Financial Performance

In 2024, FRA:B6E's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK